Overview
Switzerland-based orthopedic solutions provider's FY 2025 revenue grew 18.5% in constant currency
FY 2025 revenue slightly missed analyst expectations
Company created 258 new jobs to foster further growth
Outlook
Medacta did not provide specific guidance for future quarters or years
Result Drivers
GEOGRAPHIC GROWTH - Substantial revenue growth across all geographic markets, led by Asia Pacific and North America
INNOVATION AND EDUCATION - Differentiating innovations and medical education drove growth across business lines
SUPPLY CHAIN OPTIMIZATION - New automated warehouse in Italy to reduce handling costs in EMEA
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Slight Miss*
EUR 683.80 mln
EUR 687.40 mln (4 Analysts)
FY Revenue Growth
18.50%
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Medacta Group SA is CHF161.00, about 3.7% below its February 2 closing price of CHF167.20
The stock recently traded at 36 times the next 12-month earnings vs. a P/E of 31 three months ago
Press Release: ID:nEQ5SBG21a
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)